Biosimilars and Rheumatoid Arthritis | Making the switch

23 March 2018

The aim of this film is to inform people in an easy-to-understand, accessible format:

  • What biosimilars are
  • Why they have been approved for use in the UK
  • What that may mean for patients and health professionals.

NRAS believes biosimilars to be an important addition to available treatments for autoimmune conditions including rheumatoid arthritis. They are a lower cost alternative to originator drugs. This allows the NHS to make potential savings when switching patients from an originator treatment to a biosimilar.

This animation would be an ideal aid for health professionals when discussing switching to a biosimilar with patients. We encourage health professionals to signpost their patients to this excellent resource which will help reduce any concerns or anxieties they individual may have.